香港IPO遇冷：发行人在最后关头撤回上市计划

NextFin News — Homei Pharmaceutical was scheduled to ring the Hong Kong exchange’s bell on November 9. Days earlier it delayed the global offering, returned application funds, and blamed current market conditions. The deal had already drawn cornerstone commitments from four mainland mutual-fund houses and targeted as much as about HK$1.04 billion at a HK$15.5–18.9 price range.It was not an isolated retreat. From September through early November, at least five companies—including Sifang Jinchuang, Junxin Shares, Slender West Lake Cultural Tourism, Weiyi Intelligent Manufacturing, and Homei—paused Hong Kong listings after advancing deep into the process. Several had passed the listing hearing. One, Slender West Lake, drew more than 3,000 times coverage in the Hong Kong public tranche yet still stopped when the international book failed to fill.Earlier in 2026 the pipeline looked crowded. Research tallies put first-quarter new filing volume above 140 companies, a multi-year high for a single quarter. By late September the front door had closed. Exchange disclosure pages show no conventional first-time listing applicant since September 29. Subsequent filings have largely been re-applications after prior documents expired, coordinator updates, or non-standard vehicles. The gap has already outlasted a quieter stretch in late 2024.The back of the line is still long. As of early October, hundreds of projects remained in the queue, with mainland A-share issuers seeking a Hong Kong listing accounting for roughly a third of the stock—far above the single-digit share typical before this cycle. Clearing that backlog at recent issuance rates would take years, not months.Full-year 2026 new-issue statistics still look respectable by longer history: break rates and first-day returns, taken across the year, are among the better readings since 2018. The third quarter tells a different story. Break rates rose sharply, average first-day gains compressed, and the median outcome flattened. Of the twenty most recent Hong Kong debuts tracked into early November, a clear majority traded below issue price. Several October listings opened lower on day one.Bankers and sponsors have pointed to the same tension: proposed valuations sitting above what secondary-market risk appetite will support, higher funding costs after Hong Kong interbank rates rose earlier in the year, and slower southbound inflows than in the prior year. When the public book is hot and the institutional book is not, the deal often cannot close on terms the issuer will accept.Some mainland companies have stopped waiting. Nearly twenty A-share names have terminated Hong Kong plans this year, ranging from consumer and software firms to larger industrial groups. Sunwoda, among the biggest to walk away, cited market conditions and its own plans after repeated filing expiries, and separately arranged a large minority investment into a battery subsidiary. Management said the decision would not materially impair operations.Others are still stepping up. A fresh batch of names—including energy storage, semiconductor, and tech issuers—has been scheduled to list in the same week Homei’s delay became public. Early trading in at least one of those debuts was sharply higher, a reminder that selective demand has not disappeared.The pattern is less a collapse of the Hong Kong listing franchise than a re-pricing of patience. Issuers that raced to file when windows looked open are now measuring whether the capital raised is worth the discount and the aftermarket risk. Investors who chased every book are sorting harder. The queue remains. The willingness to finish the last mile does not. 更多精彩内容，关注钛媒体微信号（ID：taimeiti），或者下载钛媒体App